Researchers at Rockefeller University have found that the body metabolizes estrogen into several forms that can impact cancer development. One form can inhibit cancer formation; the other encourages tumor development. Specifically, these “good” estrogens are called 2-hydroxyestrone (2-OHE1), 2-hydroxyestradiol (2-OHE2), 2-methoxyestrone (2-OMeE1), and 4-methoxyestrone (4-OMeE1). The “bad” ones are called 4-hydroxyestrone (4-OHE1) and 16-α-hydroxyestrone (16α-OHE1). Through urine testing we can evaluate the levels of these estrogens within the body.
How does urine testing work? Imbalances between these two classes of estrogens may influence the development of conditions such as breast cancer, colorectal cancer, prostate cancer, uterine cancers (including endometrial cancer), ovarian cancer, cervical cancer, head and neck cancers, poly-cystic ovarian syndrome, uterine fibroids, endometriosis, preeclampsia, osteoporosis, menopausal symptoms, and premenstrual syndrome. By determining the ratio of these estrogens to each other, we can project long-term risks. For example, a 2-OHE:16α-OHE1 ratio that is less than 2.0 indicates an increasing long-term risk for breast, cervical, and other estrogen-sensitive cancers. With proper nutrition, we can effectively raise these low ratios to minimize your long-term risks.
How do I take the test? We will send you the collection material for the test. Once ready, you collect your first-morning urine sample and send it to our preferred lab, Metametrix. After processing, we evaluate the data and contact you with the results.